The use of FoxP3 as a biomarker and prognostic factor for malignant human tumors

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 10, 2007, Pages 1931-1934

  Schreiber, Taylor H ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Pap Building no 328 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3;

IMMUNE SYSTEM; IMMUNOSURVEILLANCE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; FORKHEAD TRANSCRIPTION FACTORS; GENETIC MARKERS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 35448977640     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0396     Document Type: Review

References (41)

1. Dye ES, North RJ. Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression. Transplantation 1984;37:600-5.
2. North RJ. Models of adoptive T-cell-mediated regression of established tumors. Contemp Top Immunobiol 1984;13:243-57.
3. North RJ. The murine antitumor immune response and its therapeutic manipulation. Adv Immunol 1984;35:89-155.
4. Borberg H, Oettgen HF, Choudry K, Beattie EJ, Jr. Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors. Int J Cancer 1972;10:539-47.
5. Rosenberg SA, Terry WD. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977;25:323-88.
6. Podack ER, Hengartner H, Lichtenheld MG. A central role of perforin in cytolysis? Annu Rev Immunol 1991;9:129-57.
7. Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 1998;188:1611-9.
8. Smyth MJ, Kershaw MH, Darcy PK, Trapani JA. Adoptive transfer: the role of perforin in mouse cytotoxic T lymphocyte rejection of human tumor xenografts in vivo. Xenotransplantation 1998;5:146-53.
9. van den Broek MF, Hengartner H. The role of perforin in infections and tumour surveillance. Exp Physiol 2000;85:681-5.
10. Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
11. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556-61.
12. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
13. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
14. Torgerson TR. Regulatory T cells in human autoimmune diseases. Springer Semin Immunopathol 2006;28:63-76.
15. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-6.
16. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
18. Bui JD, Uppaluri R, Hsieh CS, Schreiber RD. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 2006;66:7301-9.
19. Nakamura T, Shima T, Saeki A, et al. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007;98:874-81.
20. Molling JW, de Gruijl TD, Glim J, et al. CD4(+)CD25(hi) regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 2007;121:1749-55.
21. Ling KL, Pratap SE, Bates GJ, et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 2007;7:7.
22. Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007;13:902-11.
23. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-39.
24. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-93.
25. Yano H, Ishida T, Inagaki A, et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 2007;120:2052-7.
26. Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmstrom PU, Totterman TH. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol 2007;177:353-8.
27. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-80.
28. Mourmouras V, Fimiani M, Rubegni P, et al. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases. Br J Dermatol 2007;157:531-9.
29. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866-72.
30. Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-405.
31. Wald O, Izhar U, Amir G, et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol 2006;177:6983-90.
32. Ikemoto T, Yamaguchi T, Morine Y, et al. Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 2006;33:386-90.
33. Rudge G, Barrett SP, Scott B, van Driel IR. Infiltration of a mesothelioma by IFN-γ-producing cells and tumor rejection after depletion of regulatory T cells. J Immunol 2007;178:4089-96.
34. Fox SB, Launchbury R, Bates GJ, et al. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2α but not HIF-1α. Prostate 2007;67:623-9.
35. Hilchey SP, De A, Rimsza LM, Bankert RB, Bernstein SH. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells. J Immunol 2007;178:4051-61.
36. Lee AM, ClearAJ, Calaminici M, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052-9.
37. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957-64.
38. Rougier P, Mitry E, Barbare JC, Taieb J. Hepatocellular carcinoma (HCC): an update. Semin Oncol 2007;34:S12-20.
39. Simova J, Bubenik J, Bieblova J, Rosalia RA, Fric J, Reinis M. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours. Int J Oncol 2006;29:1567-71.
40. El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006;105:430-7.
41. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 2007;67:371-80.